GlassScriptPhysician profile
Wayne Charles Jones
NPI 1457470528
$3,998.55
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,190 · 2020: $592 · 2021: $1,703 · 2022: $472 · 2023: $42.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $42.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $42.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $436.68 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $413.41 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $360.97 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $355.82 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $334.29 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $246.43 | 2019-2022 | |
| Allergan, INC. | $244.32 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $196.98 | 2019-2022 | |
| Eisai INC. | $196.60 | 2021-2022 | |
| Validus Pharmaceuticals LLC | $158.65 | 2019-2021 | |
| Bausch Health US, LLC | $157.25 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $127.81 | 2020-2023 | Rexulti |
| Neos Therapeutics, LP | $107.84 | 2019-2023 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $93.58 | 2021 | |
| Abbvie INC. | $70.79 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $65.74 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $64.03 | 2021 | |
| Almatica Pharma LLC | $60.94 | 2021-2022 | |
| Corium, LLC | $58.46 | 2021-2022 | |
| Aytu Biopharma, INC. | $48.92 | 2019-2020 | |
| Acerus Pharmaceuticals Corporation | $41.68 | 2021-2022 | |
| Adlon Therapeutics L.P. | $37.98 | 2019-2021 | |
| Harmony Biosciences LLC | $19.22 | 2020 | |
| Antares Pharma, INC. | $16.75 | 2020 | |
| Noven Therapeutics, LLC | $16.04 | 2020 | |
| Sunovion Pharmaceuticals INC. | $15.86 | 2022 | |
| Azurity Pharmaceuticals, INC. | $14.25 | 2023 | Horizant |
| Ibsa Pharma INC. | $13.26 | 2021 | |
| Novo Nordisk INC | $12.89 | 2020 | |
| Currax Pharmaceuticals LLC | $11.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.